Spero Therapeutics (SPRO) Income from Continuing Operations (2016 - 2026)

Spero Therapeutics has reported Income from Continuing Operations for 11 years, with the latest figure at 7202000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 48.06% year-over-year to 7202000.0; the trailing twelve-month figure through Mar 2026 stood at 15230000.0 (up 120.72% YoY), and the FY2025 full-year result was 8565000.0, up 112.48% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 7202000.0, down from 31520000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 55111000.0 in Q4 2023, with the low at 30135000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 4957176.47 across 5 years, with a median of 11908000.0 in 2023.
• Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 454.02% — and 2025, when it soared 230.92%.
• Spero Therapeutics' Income from Continuing Operations stood at 27486000.0 in 2022, then surged by 100.51% to 55111000.0 in 2023, then plunged by 143.68% to 24075000.0 in 2024, then soared by 230.92% to 31520000.0 in 2025, then tumbled by 122.85% to 7202000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 7202000.0 (Q1 2026), 31520000.0 (Q4 2025), and 7384000.0 (Q3 2025), per Business Quant data.